FORM 7  
  
MONTHLY PROGRESS REPORT

Name of Listed Issuer: WINSTON RESOURCES INC. (the “Issuer”).

Trading Symbol: WRW

Number of Outstanding Listed Securities: 25,133,840

Date: February 7, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**On January 12th, 2018, the Company announced that it has entered into an assignment and novation agreement dated effective Jan. 10, 2018, among the company, GT Therapeutics Corp. (doing business as Green Tree Therapeutics (GTT)), certain shareholders of GTT and Abattis Bioceuticals Corp.**

**Pursuant to the terms of the assignment agreement, the company has assigned all of its rights and interest under the share exchange agreement dated effective May 31, 2017, with GTT. The share exchange agreement relates to an acquisition of all of the issued and outstanding shares of GTT (see press releases dated Feb. 27, 2017, and June 1, 2017, for further details). In connection with the assignment, Abattis, GTT and certain shareholders of GTT have entered into a definitive agreement to acquire all of the issued and outstanding shares of GTT from the GTT shareholders.**

**In consideration of the assignment and subject to the completion of the transaction and the approval of the Canadian Securities Exchange, Abattis will issue 15 million common shares in the capital of Abattis to the company.**

**On January 29th, 2018, the Company announced that Winston Resources Inc.'s assignee, Abattis Bioceuticals Corp., has completed its acquisition of Green Tree Therapeutics.**

**Pursuant to the terms of an assignment and novation agreement dated effective Jan. 10, 2018, among the company, Abattis, Green Tree and certain shareholders of Green Tree, the company assigned to Abattis all of its rights and interest under a share exchange agreement dated effective May 31, 2017, between the company and Green Tree, pursuant to which the company was granted the right to acquire Green Tree (see news releases dated Feb. 27, 2017, and June 1, 2017, for further details).**

**In consideration of the assignment and upon closing of the acquisition, Abattis issued 15 million common shares to the company.**

1. Provide a general overview and discussion of the activities of management.

**On January 12th, 2018, the Company announced that it has entered into an assignment and novation agreement dated effective Jan. 10, 2018, among the company, GT Therapeutics Corp. (doing business as Green Tree Therapeutics (GTT)), certain shareholders of GTT and Abattis Bioceuticals Corp.**

**On January 29th, 2018, the Company announced that Winston Resources Inc.'s assignee, Abattis Bioceuticals Corp., has completed its acquisition of Green Tree Therapeutics.**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**On January 29th, 2018, the Company announced that Winston Resources Inc.'s assignee, Abattis Bioceuticals Corp., has completed its acquisition of Green Tree Therapeutics.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**On January 29th, 2018, the Company announced that Winston Resources Inc.'s assignee, Abattis Bioceuticals Corp., has completed its acquisition of Green Tree Therapeutics.**

**Pursuant to the terms of an assignment and novation agreement dated effective Jan. 10, 2018, among the company, Abattis, Green Tree and certain shareholders of Green Tree, the company assigned to Abattis all of its rights and interest under a share exchange agreement dated effective May 31, 2017, between the company and Green Tree, pursuant to which the company was granted the right to acquire Green Tree (see news releases dated Feb. 27, 2017, and June 1, 2017, for further details).**

**In consideration of the assignment and upon closing of the acquisition, Abattis issued 15 million common shares to the company.**

1. Describe the acquisition of new customers or loss of customers.

**Not applicable.**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**There were no new developments.**

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None.**

1. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**There are no legal proceedings.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

1. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds(1)** |
|  |  |  |  |

1. *State aggregate proceeds and intended allocation of proceeds.*
2. Provide details of any loans to or by Related Persons.

**None.**

1. Provide details of any changes in directors, officers or committee members.

**None.**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**There are no trends specific to the Issuer at this time.**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: February 7, 2018

Name of Director or Senior Officer

Quinn Field-Dyte

*“Quinn Field-Dyte”*

CEO, Director

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***  Name of Issuer  WINSTON RESOURCES INC. | For Month End  January 2018 | Date of Report  YY/MM/D  18/02/07 |
| Issuer Address  #800 – 1199 W. Hastings Street | | |
| City/Province/Postal Code  Vancouver, BC V6E 3T5 | Issuer Fax No.  (888)241-5996 | Issuer Telephone No.  (604)283.1722 |
| Contact Name  Von Torres | Contact Position  Director | Contact Telephone No.  (604)283.1722 |
| Contact Email Address  corporate@bridgemark.com | Web Site Address  NA | |